Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Follow-up care over 12months of patients with prostate cancer in Spain A multicenter prospective cohort study

  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Vernooij, Robin W. M.|||0000-0001-5734-4566
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Morales-Suárez-Varela, María|||0000-0003-0785-1492
  • Emparanza, José Ignacio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Pijoan, José Ignacio
  • Palou, Juan|||0000-0003-1264-5327
  • Madrid, Eva|||0000-0002-8095-5549
  • Abraira, Víctor|||0000-0002-4615-8503
  • Zamora, Javier|||0000-0003-4901-588X
The therapeutic approach is crucial to prostate cancer prognosis. We describe treatments and outcomes for a Spanish cohort of patients with prostate cancer during the first 12 months after diagnosis and identify the factors that influenced the treatment they received. This multicenter prospective cohort study included patients with prostate cancer followed up for 12 months after diagnosis. Treatment was stratified by factors such as hospital, age group (<70 and ≥70 years), and D'Amico cancer risk classification. The outcomes were Eastern Cooperative Oncology Group (ECOG) performance status, adverse events (AEs), and mortality. The patient characteristics associated with the different treatment modalities were analyzed using multivariate logistic regression. We included 470 men from 7 Spanish tertiary hospitals (mean (standard deviation) age 67.8 (7.6) years), 373 (79.4%) of which received treatment (alone or in combination) as follows: surgery (n = 163; 34.7%); radiotherapy (RT) (n = 149; 31.7%); and hormone therapy (HT) (n = 142; 30.2%). The remaining patients (n = 97) were allocated to no treatment, that is, watchful waiting (14.0%) or active surveillance (5.7%). HT was the most frequently administered treatment during follow-up and RT plus HT was the most common therapeutic combination. Surgery was more frequent in patients aged <70, with lower histologic tumor grades, Gleason scores <7, and lower prostate-specific antigen levels; while RT was more frequent in patients aged ≥70 with histologic tumor grade 4, and higher ECOG scores. HT was more frequent in patients aged ≥70, with histologic tumor grades 3 to 4, Gleason score ≥8, ECOG ≥1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly during follow-up, from 75.3% at diagnosis to 65.1% at 12 months (P <.001); 230 (48.9%) patients had at least 1 AE, and 12 (2.6%) patients died. Surgery or RT were the main curative options. A fifth of the patients received no treatment. Palliative HT was more frequently administered to older patients with higher tumor grades and higher Gleason scores. Close to half of the patients experienced an AE related to their treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Follow-up care of 12 months of patients with bladder cancer in Spain, A multicenter prospective cohort study

  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Barrionuevo-Rosas, Leslie
  • Vernooij, Robin W. M.|||0000-0001-5734-4566
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Morales-Suárez-Varela, María|||0000-0003-0785-1492
  • De la Cruz, Javier|||0000-0002-2010-4128
  • Emparanza, José Ignacio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Pijoan, José Ignacio
  • Palou, Juan|||0000-0003-1264-5327
  • Frances, Albert
  • Madrid, Eva|||0000-0002-8095-5549
  • Coscia, Claudia
  • Zamora, Javier|||0000-0003-4901-588X
The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received. We conducted a multicenter, prospective, cohort study including primary bladder cancer patients during the first 12 months after diagnosis. The clinical outcomes were performance status (ECOG), adverse events and any cause of mortality. We stratified the analysis by factors that might influence the treatments received. We conducted univariate and multivariable logistic regression models to assess which patient and tumor characteristics were associated with receiving adjuvant treatment in the subgroup of noninvasive bladder cancer patients. In total, 314 patients were included (85% men; 53.8%.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury, A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial

  • Garg, Amit X.|||0000-0003-3398-3114
  • Cuerden, Meaghan
  • Aguado, Héctor J.|||0000-0002-0371-520X
  • Amir, Mohammed
  • Belley-Cote, Emilie P.
  • Bhatt, Keyur
  • Biccard, Bruce M.|||0000-0001-5872-8369
  • Kessler Borges, Flavia|||0000-0001-5377-7612
  • Chan, Matthew
  • Conen, David
  • Duceppe, Emmanuelle|||0000-0002-1457-2945
  • Efremov, Sergey
  • Eikelboom, John
  • Fleischmann, Edith
  • Giovanni, Landoni
  • Gross, Peter
  • Jayaram, Raja
  • Kirov, Mikhail
  • Kleinlugtenbelt, Ydo
  • Kurz, Andrea
  • Lamy, Andre
  • Leslie, Kate
  • Likhvantsev, Valery
  • Lomivorotov, Vladimir
  • Marcucci, Maura|||0000-0002-8468-7991
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • McGillion, Michael
  • McIntyre, William
  • Meyhoff, Christian
  • Ofori, Sandra|||0000-0002-1691-0979
  • Painter, Thomas
  • Paniagua, Pilar|||0000-0002-0215-1561
  • Parikh, Chirag
  • Parlow, Joel
  • Patel, Ameen|||0000-0002-9338-2815
  • Polanczyk, Carisi
  • Richards, Toby
  • Roshanov, Pavel
  • Schmartz, Denis
  • Sessler, Daniel|||0000-0001-9932-3077
  • Short, Tim
  • Sontrop, Jessica M.|||0000-0001-7784-2028
  • Spence, Jessica|||0000-0003-1267-9455
  • Srinathan, Sadeesh
  • Stillo, David
  • Szczeklik, Wojciech|||0000-0002-1349-1123
  • Tandon, Vikas
  • Torres, David
  • Van Helder, Thomas
  • Vincent, Jessica|||0000-0002-2356-8876
  • Wang, C.Y.
  • Wang, Michael Ke|||0000-0002-4949-3235
  • Whitlock, Richard
  • Wittmann, Maria|||0000-0003-4786-7712
  • Xavier, Denis
  • Devereaux, P. J.|||0000-0003-2935-637X
Background: Most patients who take antihypertensive medications continue taking them on the morning of surgery and during the perioperative period. However, growing evidence suggests this practice may contribute to perioperative hypotension and a higher risk of complications. This protocol describes an acute kidney injury substudy of the Perioperative Ischemic Evaluation-3 (POISE-3) trial, which is testing the effect of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy in patients undergoing noncardiac surgery. Objective: To conduct a substudy of POISE-3 to determine whether a perioperative hypotension-avoidance strategy reduces the risk of acute kidney injury compared with a hypertension-avoidance strategy. Design: Randomized clinical trial with 1:1 randomization to the intervention (a perioperative hypotension-avoidance strategy) or control (a hypertension-avoidance strategy). Intervention: If the presurgery systolic blood pressure (SBP) is <130 mmHg, all antihypertensive medications are withheld on the morning of surgery. If the SBP is ≥130 mmHg, some medications (but not angiotensin receptor blockers [ACEIs], angiotensin receptor blockers [ARBs], or renin inhibitors) may be continued in a stepwise manner. During surgery, the patients' mean arterial pressure (MAP) is maintained at ≥80 mmHg. During the first 48 hours after surgery, some antihypertensive medications (but not ACEIs, ARBs, or renin inhibitors) may be restarted in a stepwise manner if the SBP is ≥130 mmHg. Control: Patients receive their usual antihypertensive medications before and after surgery. The patients' MAP is maintained at ≥60 mmHg from anesthetic induction until the end of surgery. Setting: Recruitment from 108 centers in 22 countries from 2018 to 2021. Patients: Patients (~6800) aged ≥45 years having noncardiac surgery who have or are at risk of atherosclerotic disease and who routinely take antihypertensive medications. Measurements: The primary outcome of the substudy is postoperative acute kidney injury, defined as an increase in serum creatinine concentration of either ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours of randomization or ≥50% within 7 days of randomization. Methods: The primary analysis (intention-to-treat) will examine the relative risk and 95% confidence interval of acute kidney injury in the intervention versus control group. We will repeat the primary analysis using alternative definitions of acute kidney injury and examine effect modification by preexisting chronic kidney disease, defined as a prerandomization estimated glomerular filtration rate <60 mL/min/1.73 m. Results: Substudy results will be analyzed in 2022. Limitations: It is not possible to mask patients or providers to the intervention; however, objective measures will be used to assess acute kidney injury. Conclusions: This substudy will provide generalizable estimates of the effect of a perioperative hypotension-avoidance strategy on the risk of acute kidney injury.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3), a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery

  • Marcucci, Maura|||0000-0002-8468-7991
  • Painter, Thomas W.
  • Conen, David
  • Leslie, Kate
  • Lomivorotov, Vladimir V.
  • Sessler, Daniel|||0000-0001-9932-3077
  • Chan, Matthew T.V.
  • Kessler Borges, Flavia|||0000-0001-5377-7612
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Wang, Chew Yin|||0000-0002-9066-3830
  • Xavier, Denis
  • Ofori, Sandra N.
  • Landoni, Giovanni|||0000-0002-8594-5980
  • Efremov, Sergey
  • Kleinlugtenbelt, Ydo V.
  • Szczeklik, Wojciech|||0000-0002-1349-1123
  • Schmartz, Denis
  • Garg, Amit X.|||0000-0003-3398-3114
  • Short, Timothy G.
  • Wittmann, Maria|||0000-0003-4786-7712
  • Meyhoff, Christian S.
  • Amir, Mohammed
  • Torres, David
  • Patel, Ameen|||0000-0002-9338-2815
  • Duceppe, Emmanuelle|||0000-0002-1457-2945
  • Ruetzler, Kurtz
  • Parlow, Joel
  • Tandon, Vikas
  • Wang, Michael K.
  • Fleischmann, Edith
  • Polanczyk, Carisi A.
  • Jayaram, Raja
  • Astrakov, Sergey V.
  • Rao, Mangala|||0000-0002-0579-1097
  • VanHelder, Tomas
  • Wu, William K.K.
  • Cheong, Chao Chia
  • Ayad, Sabry
  • Abubakirov, M.
  • Kirov, Marat
  • Bhatt, Keyur
  • Nadal Clanchet, Miriam de|||0000-0002-4559-2463
  • Likhvantsev, Valery
  • Paniagua, Pilar|||0000-0002-0215-1561
  • Aguado, Héctor J.|||0000-0002-0371-520X
  • McGillion, Michael
  • Lamy, Andre
  • Whitlock, Richard P.
  • Roshanov, Pavel
  • Stillo, David
  • Copland, Ingrid
  • Vincent, Jessica|||0000-0002-2356-8876
  • Balasubramanian, Kumar
  • Bangdiwala, Shrikant I.
  • Biccard, Bruce M.|||0000-0001-5872-8369
  • Kurz, Andrea
  • Srinathan, Sadeesh
  • Petit, Shirley
  • Eikelboom, John
  • Richards, Toby
  • Gross, Peter L.
  • Alfonsi, Pascal
  • Guyatt, Gordon|||0000-0003-2352-5718
  • Belley-Cote, Emily
  • Spence, Jessica|||0000-0003-1267-9455
  • McIntyre, William
  • Yusuf, Salim
  • Devereaux, P. J.|||0000-0003-2935-637X
Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes. Methods: The PeriOperative Ischemic Evaluation (POISE)-3 Trial is a large international randomized controlled trial designed to determine if TXA is superior to placebo for the composite outcome of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic events, at 30 days after randomization. Using a partial factorial design, POISE-3 will additionally determine the effect of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of major cardiovascular events, at 30 days after randomization. The target sample size is 10,000 participants. Patients ≥45 years of age undergoing noncardiac surgery, with or at risk of cardiovascular and bleeding complications, are randomized to receive a TXA 1 g intravenous bolus or matching placebo at the start and at the end of surgery. Patients, health care providers, data collectors, outcome adjudicators, and investigators are blinded to the treatment allocation. Patients on ≥ 1 chronic antihypertensive medication are also randomized to either of the two blood pressure management strategies, which differ in the management of patient antihypertensive medications on the morning of surgery and on the first 2 days after surgery, and in the target mean arterial pressure during surgery. Outcome adjudicators are blinded to the blood pressure treatment allocation. Patients are followed up at 30 days and 1 year after randomization. Discussion: Bleeding and hypotension in noncardiac surgery are common and have a substantial impact on patient prognosis. The POISE-3 trial will evaluate two interventions to determine their impact on bleeding, cardiovascular complications, and mortality. Trial registration: ClinicalTrials.gov NCT03505723. Registered on 23 April 2018.